Furthermore, in a clinical trial involving patients with metastatic colorectal cancer, local infusion of the CAR-NK cells resulted in reduced ascites generation, a marked decrease in tumor cell numbers, and rapid tumor regression in the liver region, highlighting the promising therapeutic potential of mRNA based NKG2D CAR-modified NK cells in treating metastatic colorectal cancer (39). Here, KLRK1 is linked to metastatic colorectal cancer.